Study S000676

A Randomized, Open-label, Controlled,Parallel-group Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03829891
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 60
Start: 2018-08-07
Primary completion: 2019-12-31
Lead sponsor: Xijing Hospital
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Beinaglutide; DRUG:glargine
Results posted: FALSE

Registered primary outcomes

The proportion and rate of the fasting blood glucose control. [Baseline and week 16]
Proportion of patients with glycosylated hemoglobin < 7%. [Baseline and week 16]
Changes of blood sugar variation . [Baseline and week 16]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007581	The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial. Liu X, Journal of diabetes	2023	Randomized trial	PMID 37864379 DOI	cites ClinicalTrials.gov:NCT03829891; registry reference DERIVED:37864379